Sulfinpyrazone

Sulfinpyrazone
Clinical data
Trade names	Anturan, Anturane, Apo-sulfinpyrazone
AHFS/Drugs.com	Monograph
MedlinePlus	a682339
Routes of; administration	By mouth intravenous
ATC code	M04AB02 (WHO) ;
Pharmacokinetic data
Protein binding	98–99%
Metabolism	liver
Excretion	kidney
Identifiers
	IUPAC name 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione;
CAS Number	57-96-5 ;
PubChem CID	5342;
IUPHAR/BPS	5826;
DrugBank	DB01138 ;
ChemSpider	5149 ;
UNII	V6OFU47K3W;
KEGG	D00449 ;
ChEBI	CHEBI:9342 ;
ChEMBL	ChEMBL832 ;
CompTox Dashboard (EPA)	DTXSID0023618 ;
ECHA InfoCard	100.000.325
Chemical and physical data
Formula	C23H20N2O3S
Molar mass	404.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4;
	InChI InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 ; Key:MBGGBVCUIVRRBF-UHFFFAOYSA-N ;
	(verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications

Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.^[1]

Research

Trial have found that, Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack. ^[2]

References

^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
^ Anturane Reinfarction Trial Research Group (1980-01-31). "Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction". New England Journal of Medicine. 302 (5): 250–256. doi:10.1056/NEJM198001313020502. ISSN 0028-4793. PMID 6985706.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

[pmid16740561-1] Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.

[2] Anturane Reinfarction Trial Research Group (1980-01-31). "Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction". New England Journal of Medicine. 302 (5): 250–256. doi:10.1056/NEJM198001313020502. ISSN 0028-4793. PMID 6985706.

[1]

[2]